1E: Biomaterials and Nanotechnology for Cancer Modeling and Theranostics
Time: 1:30 PM to 3:30 PM
Description
This symposium will highlight advances in biomaterial- and nanomaterial-based platforms that are transforming cancer research, diagnosis, and therapy. Biomaterials-based cancer models closely mimic the tumor microenvironment, enabling integration of multiple cell types, tunable matrices, patient-relevant treatments (e.g., radiation), and high-resolution mechanistic analysis to accelerate therapeutic development with improved efficacy and reduced toxicity. Complementing these approaches, nanomaterials are advancing cancer theranostics through multimodal imaging, remotely actuated non-invasive therapies, and innovative immunomodulatory strategies. Together, these technologies bridge physiologically relevant cancer models with next-generation nanomedicine to enhance therapeutic precision and clinical translation.
Moderators:
Dr. Ricardo Cruz-Acuna
Assistant Professor of Cancer Engineering
Columbia University Irving Medical Center
Daniel Harrington
Associate Professor
The University of Texas Health Science Center at Houston (UTHealth)
1:30 PM. 27. Talk by Susan Thomas, Georgia Institute of Technology
2:00 PM. 28. Engineering Hydrogel Platforms to Investigate ECM-driven Tumor Formation and Therapy Resistance in Adenocarcinoma.Daniel Garcia, BS, MA1 1Columbia University
2:15 PM. 29. 3D Droplet-Based Bioprinting for Tailorable Hydrogel Models of Head and Neck Cancer Tumor Microenvironments.Victoria Messuri1, Abbie Ha2, Daniel Harrington, PhD3 1Rice Uniersity, 2Rice University, 3The University of Texas Health Science Center at Houston
2:30 PM. 30. Liver Extracellular Matrix Exposure Induces Dormancy Signatures in Colorectal Cancer Spheroids.Lucia Nash1, Anvitha Tharakesh1, Brinlee Goggans1, Scott Kopetz, M.D., Ph.D., F.A.C.P.2, Shreya Artha Raghavan, Associate Professor1 1Texas A&M University, 2University of Texas MD Anderson Cancer Center
2:45 PM. 31. Photoacoustic Tracking of Nanoengineered NK Cells Using PLGA Nanoparticles in Combination with Radiotherapy.Brendan Barlow1, Tasneem Mukarrama2, Megan Purl2, Ana Sandoval-Castellanos, PhD2, Alexander LeBeau2, Arta Monjazeb, M.D., Ph.D.3, Sean Judge, M.D.2, Robert Canter, M.D.2, Jinhwan Kim, Ph.D.4 1University of California Davis, 2UC Davis, 3UC Davis Health, 4UC Davis Health, University of California, Davis
3:00 PM. 32. Targeting Cell-Matrix Induced Chemoresistance With Regorafenib in a 3D Model of Osteosarcoma.Rameshwar Rao, MD PhD1, Michelle Huang, PhD2, Daiyao Zhang, BS2, Carla Huerta-López, PhD2, Christopher Long, BS2, Gisele Aviles Rodriguez2, Esther Mozipo, BS2, Sriya Sagi, MS1, Sarah Heilshorn, PhD2 1Seattle Children's Research Institute, 2Stanford University
3:15 PM. 33. A 3D Osteosarcoma Model reveals Patient Heterogeneity in Drug Response and ECM Remodeling.Varsha Naga, B.S.1, Jeehee Lee, PhD1, Fan Yang, PhD1 1Stanford University